Australia: Government signals reforms to address concerns over gene patents

Last Updated: 16 August 2012
Article by Catherine Logan

Tip #1: Make use of the new experimental use exemption and the additional regulatory approval exemption that came into effect 15 April 2012.

Tip #2: File your patent applications before 15 April 2013 if you want the benefit of the current patent laws.

Tip 3#: Stakeholders and interested parties should consider making submissions to parliament once public consultation commences to give effect to the upcoming changes signaled by the government's Response Paper.


Our article " Raising the bar? The new patent law reforms and their impact on patentability of genetic material" ("August article"), published in the August 2011 issue of the AIPLB, explored upcoming reforms to Australian patent laws by the Intellectual Property Laws Amendment (Raising the Bar) Bill 2011 ("Bill") in the context of gene patents. In particular, we discussed the litigation in the US and in Australia over patents of two genes that are associated with the development of breast and ovarian cancer1("BRCA genes").

The BRCA litigation raises a number of issues canvassed in a growing list of inquiries and reports over recent years on gene patents by the Australian Law Reform Commission2, the Senate Community Affairs Reference Committee3, the Australian Council for Intellectual Property (ACIP)4, and the Senate Legal and Constitutional Affairs Legislation Committee5. Towards the end of November last year the Government released a Response Paper6 in reply to the recommendations made in these reports.

In this article, we will provide a legislation and litigation update, and examine how the Response Paper seeks to address community concerns and public health access issues in the area of gene patents.


Since the August article, the Bill has passed through both houses of Parliament unamended, and the consequential Intellectual Property Laws Amendment (Raising the Bar) Act 2012 ("Raising the Bar Act") received Royal Assent on 15 April 2012. While most of the provisions in the Act will commence on 15 April 2013, the following two patent infringement exemptions immediately came into force:

  1. Regulatory approval exemption (for non-pharmaceutical patents) to allow activities that would otherwise be an infringement of a patent, if the activities are for the sole purpose of obtaining regulatory approval to enter the market upon expiry of a patent7; and
  2. Experimental use exemption to allow patents to be exploited for a primarily experimental purpose8.


Myriad Genetics Inc continues to make headlines in the US in the ongoing litigation on the validity of the BRCA patents. Since the August article, the US federal Court of Appeals overturned a 2010 District Court decision that invalidated the BRCA patents. While the biotechnology industry breathed a brief sigh of relief, the American Civil Liberties Union and Public Patent Foundation appealed to the Supreme Court.

On 26 March 2012, the US Supreme Court overturned the appeals court's decision and has remitted the Myriad Case to the appeals court for reconsideration. The Supreme Court applied a recent decision in Mayo Collaborative Services v Prometheus Laboratories Inc 9 ("the Prometheus Case"), where claims relating to a method of blood test were not patentable as they were not more than "natural relations". In that case, the Supreme Court held that patentable materials must be more than a law of nature or a process that recites a law of nature. The question that remains is whether the same principle in the Prometheus Case applies to the BRCA patents – the former being a patent of diagnostic methods and the latter being gene patents.

In Australia, the Federal Court hearing on the same BRCA patents was held in late February this year.10 The pending decision of Nicholas J is much awaited by the biotechnology industry, health service providers, and cancer patients alike. GOVERNMENT RESPONSE PAPER ON GENE PATENTS

The topic of gene patents and its impact on public health is an area that until now has not been directly addressed by the Government. The Response Paper suggests that the major focus of the next wave of patent reform after the Raising the Bar Act will centre around genetic and biotechnology patents.

Senator Kim Carr, the Minister for Innovation, Industry, Science and Research has stated that the government's approach in the Response Paper is designed to give confidence to investment in biotechnology investment while also ensuring that "patients will not be denied reasonable access to affordable treatments and essential diagnostic tests through inappropriate use of the Patents Act".11

We have extracted some significant points from the Response Paper.

No special legislative test for patents relating to genetic materials

The Response Paper has accepted the ALRC recommendation against excluding genetic materials and technologies, or methods of diagnostic, therapeutic or surgical treatment, from patentable subject matter. The Government agreed with the ALRC that "patent applications relating to genetic materials and technologies should be assessed according to the same legislative criteria for patentability that apply to patent applications relating to any other type of technology".

In addition, the Government has stated that it considers the current examination guidelines published in the Australian Patent Office Manual of Practice and Procedure apply sufficiently to inventions involving genetic materials and technologies.

In doing so, the Response Paper puts another nail in the coffin of the much criticised Patent Amendment (Human Genes and Biological Materials) Bill 2010 (No 2) (Cth), which sought to broadly prohibit the patenting of biological and genetic materials. However, this issue remains live in the political arena with Labor MP Melissa Parke's recent announcement on the imminent introduction of a similar private members bill to ban patents on genes.12

Patents should not lead to patients being denied reasonable access to healthcare

The Government has accepted recommendations by the Senate and ACIP to introduce a statement of objectives into the Patents Act 1990 (Cth). In particular, the Response Paper singles out the Government's intention to clarify that a patent should not lead to patients being denied reasonable access to health care.

A statement of objectives will be influential on patent examiners and the courts when public access health issues are raised in the context of the proposed "wholly offensive" invention exclusion.

Re-define patentable subject matter using clear and contemporary language

Patent practitioners will know that one component of the current test for patentability in s 18(1)(a) of the Patents Act 1900 (Cth) requires an invention to be a "method of manufacture" within the meaning of section 6 of the Statute of Monopolies 1623. Aside from being written in archaic English, the Statute of Monopolies did not in fact define "method of manufacture"13. While the test has been clarified by case law, it overlaps with the other tests of novelty, inventive step and usefulness. Both the ALRC and ACPI have recommended legislative intervention.

In accepting these recommendations, the Response Paper gave specific recognition to health-related patents. The Response Paper noted that any reform to the test of patentability will take into account the role of patents in commercialising health research, and the need to provide industry with certainty balanced against strong public concern about affordable access to health care.

Exclude from patentability inventions that are "wholly offensive"

In the August 2011 article, the authors noted that a research exemption is insufficient to cover the range of public health access issues that do not fall neatly within the definition of "experimental use". We considered that the Act failed to acknowledge the ACIP recommendation to exclude from patentability inventions that are wholly offensive to an ordinary, reasonable and fully informed member of the public.

The Response Paper has now accepted this recommendation. While it remains to be seen what type of inventions will be caught by this exclusion, the ACIP envisions that examples include a patent for a genetically modified mouse that is highly susceptible to cancer and patents relating to stem cells that involve the destruction of human embryos.14

Government may intervene if a gene patent adversely impacts medial research or cost-effective healthcare

Though the Response Paper has rejected the direct use of government funds and purchasing power to control the costs of health care related gene patents, it is possible that governments may exercise broad legal interference with patent holder rights in certain circumstances.

The Response Paper has accepted "in principle" that where gene patents may have an adverse impact on medical research or cost-effective healthcare, Commonwealth or State governments should have the legal option to:

  • oppose an existing patent application;
  • make a complaint to the ACCC where there is evidence of potential restrictive trade practices;
  • exploit or acquire the patent under Crown use and acquisition provisions; or
  • apply for the grant of a compulsory licence.

The Government has flagged the National Health and Medical Research Council (NHMRC) and the Medical Services Advisory Committee as the appropriate bodies to provide technical and economic advice on health related inventions.

In addition, the Government has signalled a review of existing compulsory licensing provisions under the Patents Act 1990 (Cth) to ensure access is given when the public benefit demands it. [*]

Patents granted as a result of publicly funded research should benefit the public

While over half of human health related research in Australia is either wholly or partially funded by the Government15, the ALRC has pointed out the need to clarify ownership, use and commercial exploitation to ensure that publicly funded research results in a public benefit.

The Response Paper has accepted a number of recommendations made by the ALRC, including a review by the NHMRC and Australian Research Council (ARC) on the existing guidelines on publicly funded research to:

  1. provide guidance on the meaning of "public benefit";
  2. assist organisations in determining the appropriateness of commercialising research results; and
  3. identify appropriate approaches to exploiting IP rights in certain circumstances.


It is clear from the Response Paper that the Government has attempted to balance community and public health access concerns against patent holder rights and commercial consideration for the biotechnology industry. How the balance is struck and the practical effect on the key stakeholders remains to be determined.

While no date has been set for the legislative mechanisms to commence work, the Government has indicated that there will be a public consultation process for the resulting draft legislation. Interested parties should keep a close eye on the window period to make submissions to Parliament.

In the interim, the pending Federal Court decision in relation to the BRCA patents will cause further impact on stakeholders.

* Authors' note: Since the writing of this article, the Government has asked the Productivity Commission to review the compulsory licencing provisions in the Patents Act 1990 (Cth). The Commission will be accepting submissions from key stakeholders and the public until 28 September 2012. The result of this inquiry will affect gene patents as well as other patents that have a public interest element. More information about the Commission's inquiry can be found at

1 Cancer Voices Australia (ABN 93 322 703 427) v Myriad Genetics Inc, Federal Court of Australia File NSD643.2010.
2 Australian Law Reform Commission "Genes and Ingenuity: Gene Patenting and Human Health" Report 99 August 2001.
3 Senate Community Affairs Reference Committee Report "Gene Patents" November 2010.
4 Advisory Council on Intellectual Property "Patent Subject Matter: Final Report" December 2010.
5 Senate Legal and Constitutional Affairs Legislation Committee "Patent Amendment (Human Genes and Biological Materials) Bill 2010" September 2011.
6 Australian Government Response to Senate Community Affairs Reference Committee Gene Patent Report, November 2011 available at
7 Patents Act 1990 (Cth) s 119B. This is an extension of the existing regulatory exemption for pharmaceutical patents in s 119A.
8 Patents Act 1990 (Cth) s 119C.
9 Case No 1150 Supreme Court (20 March 2012).
10 Cancer Voices Australia (ABN 93 322 703 427) v Myriad Genetics Inc Federal Court of Australia File NSD643/2010.
11 Senator Kim Carr "A Better Patent System to Secure Australia's Prosperity" media release (23 November 2011) available at
12 See Lateline "Push for Ban on Gene Patents" broadcast on 14 May 2012; available at
13 For those brave enough to venture thus far, s 6 of the Statute of Monopolies provides: "Provided alsoe That any Declaracion before mencioned shall not extend to any tres Patents and Graunt of Privilege for the tearme of fowerteene yeares or under, hereafter to be made of the sole working or making of any manner of new Manufactures within this Realme, to the true and first Inventor and Inventors of such Manufactures, which others at the tyme of makinge such tres Patents and Graunts shall not use, soe as alsoe they be not contrary to the Lawe nor mischievous to the State, by raisinge prices of Commodities at home, or hurt of Trade, or generallie inconvenient; the said fourteene yeares to be [accomplished] from the date of the first tres Patents or Grant of such priviledge hereafter to be made, but that the same shall be of such force as they should be if this Act had never byn made, and of none other." Available at
14 Advisory Council on Intellectual Property "Patent Subject Matter: Final Report" December 2010 at [4.2.3].
15 Australian Law Reform Commission "Genes and Ingenuity: Gene Patenting and Human Health" Report 99, June 2004 at p 601.
16 Including the Principles of Intellectual Property Management for Publicly Funded Research and Australian Code for the Responsible Conduct of Research both available at

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Catherine Logan
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Mondaq Advice Centre (MACs)
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.